18 There are many regions or countries, such as Austria, Canada and Japan that have ethics guidelines recognizing exploratory genetic results as having questionable utility and lacking the qualities useful for meaningful medical decision making.
In 2006, the FDA issued guidelines for exploratory investigational new drug (IND) studies (e.g., screening studies or microdose studies) that are conducted early in phase 1 of the trial process, involve very limited human exposure for a short time period (e.g., 7 days), and have no diagnostic intent [ 56].
In January 2006, guidelines on exploratory investigational new drug studies in humans have been published by the US FDA, and currently a Phase 0 programme is ongoing at the National Cancer Institute to evaluate the impact (feasibility and utility) of Phase 0 studies on drug development.
This exploratory study applies the PRISMA guidelines for conducting systematic reviews to the identification, screening and selection of diabetes related tweets that were posted in September 2013.
The results reported in this article were obtained conducting an exploratory case study, according to guidelines proposed in Runeson et al. [31].
Virtually all new validated end points in current guidelines originated in exploratory research.
To allow for data comparison, we used semi-structured FGD guidelines containing both exploratory questions and targeted questions.
The work presented herein on both exploratory and confirmatory analyses provide guidelines for identifying the occurrence of periodic elements and thus advancing our understanding of their role in genome organisation.
The group conducted an exploratory search for existing international guidelines in Medline (OVID), the databases of the Guidelines International Network (GIN), the Quality Dome and Artsennet, and systematic reviews in Medline (OVID) and the Cochrane Library.
Following these concepts in April 2004, US FDA published a draft guidance regulating early human screening studies, and in January 2006 new industry guidelines for early exploratory drug studies in humans have been issued (http://www.fda.gov/cder/guidance/7086fnl.htm).htm
